EN
Select language

FDA Approves Gadopiclenol Injection for the U.S. market

Monroe Township, NJ , 09/21/2022

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High Relaxivity Gadolinium Based Contrast Agent which will be commercialized as VUEWAY ™ (gadopiclenol) and VUEWAY ™ (gadopiclenol) Pharmacy Bulk Package by Bracco